Metagenomi Therapeutics (MGX) vs Tevogen (TVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Metagenomi Therapeutics (MGX) has outperformed Tevogen (TVGN) over the past year, losing 66.6% versus a loss of 80.5%. Tevogen is the larger company by market cap ($46.0 million vs $37.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGX | TVGN |
|---|---|---|
| Share price | $0.9932 | $7.06 |
| Market cap | $37.52M | $45.97M |
| 1-day change | +0.86% | +8.78% |
| YTD return | -39.22% | -57.34% |
| 1-year return | -66.62% | -80.50% |
| EPS (TTM) | $-2.49 | $-6.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.95 | $39.00 |
| 52-week low | $0.96 | $3.64 |
| Distance from 52-week high | -74.86% | -81.90% |
| Average volume | 155.71K | 9.75K |
| Shares outstanding | 37.78M | 6.51M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGX has outperformed TVGN by 13.9 percentage points over the past year.
MGX vs TVGN FAQ
Which is bigger, Metagenomi Therapeutics or Tevogen?
Tevogen (TVGN) is larger, with a market capitalization of $45.97M compared with $37.52M for Metagenomi Therapeutics (MGX).
Which stock has performed better over the past year, MGX or TVGN?
MGX returned -66.62% over the past 12 months, compared with -80.50% for TVGN (price return, excluding dividends). Past performance does not predict future results.
Are Metagenomi Therapeutics and Tevogen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.